AIM: To study the feasibility of VEGF165 gene transfection to endothelial cells and cardiac myocytes in-vitro. METHODS: The VEGF165 DNA fragment was inserted into a green fluorescent protein fusion vector, which was then transfected into endothelial cells and cardiac myocytes with lipofectamine. RESULTS: The endothelial cells and cardiac myocytes were successfully transfected with pIRES2-EGFP-hVEGF165 gene, which was confirmed by fluoroscopy and immunohistochemistry. CONCLUSION: VEGF can be expressed stably in the endothelial cells and cardiac myocytes, which might be useful for the gene therapy of myocardial ischemia.
AIM: To study the feasibility of VEGF165 gene transfection to endothelial cells and cardiac myocytes in-vitro. METHODS: The VEGF165 DNA fragment was inserted into a green fluorescent protein fusion vector, which was then transfected into endothelial cells and cardiac myocytes with lipofectamine. RESULTS: The endothelial cells and cardiac myocytes were successfully transfected with pIRES2-EGFP-hVEGF165 gene, which was confirmed by fluoroscopy and immunohistochemistry. CONCLUSION:VEGF can be expressed stably in the endothelial cells and cardiac myocytes, which might be useful for the gene therapy of myocardial ischemia.